Effect of Hypoglycemic Drugs on Patients with Heart Failure with or without T2DM: A Bayesian Network Meta-analysis.

Zhang Z, Liu S, Xian J, Zhang Y, Zhang C, Wang Z, Deng H, Feng J, Yao L

Reviews in cardiovascular medicine21 Mar 2025

PMID40160590PMCIDPMC11951290DOI10.31083/rcm26154PepBankPUB-40160590

Summary

BackgroundAnti-diabetic drugs have been noted to have a cardioprotective effect in patients with diabetes and heart failure (HF). The purpose of this study was to perform a Bayesian network meta-analysis to evaluate the impact of various anti-diabetic drugs on the prognosis of HF patients with and without diabetes.MethodsWe searched PubMed, Embase, Cochrane, and Web of Science for randomized controlled trials (RCTs) published before November 2024 that investigated the use of anti-diabetic medications in patients with HF. Primary outcomes included re-admission due to HF, all-cause death, cardiovascular death, serum N-terminal pro-brain natriuretic peptide (NTpro-BNP) levels, and left ventricular ejection fraction (LVEF). A Bayesian network meta-analysis was used to compare the effectiveness of different anti-diabetic drugs.ResultsA total of 33 RCTs involving 29,888 patients were included. Sotagliflozin was the most effective in reducing the risk of re-admission due to HF and all-cause death, with a cumulative probability of 0.84 and 0.83, respectively. Liraglutide reduced the risk of cardiovascular death in HF patients with a cumulative probability of 0.97 and had the best efficacy in reducing NTpro-BNP levels with a cumulative probability of 0.69. Empagliflozin was best in improving LVEF in HF patients, with a cumulative probability of 0.69.ConclusionsThis Bayesian network meta-analysis demonstrates that sotagliflozin may be the best option for HF patients with and without diabetes. However, due to the small number of articles in this study, our results must be treated cautiously. Subsequently, there is an urgent need for more high-quality studies to validate our findings.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewEfficacy outcome
In reviewed HF patients, liraglutide was reported to reduce cardiovascular-death risk with cumulative probability 0.97; the probability definition and original comparison were unstated.
In plain wordsIn reviewed HF patients, liraglutide showed reported cardiovascular-death reduction with cumulative probability 0.97; its definition and comparison were unspecified.
Peptide
Liraglutide
Outcome
DecreaseCardiovascular death
Study
n: not reported in source
Analysis
Primary
Outcome group
Mortality · Cardiovascular
Studied dose
Dose not stated
Measurements
Cumulative probability
0.97
as reported for cardiovascular-death reduction; probability definition/reference unspecified; probability interpretation unspecified
Source sentences
Summary
Liraglutide reduced the risk of cardiovascular death in HF patients with a cumulative probability of 0.97 and had the best efficacy in reducing NTpro-BNP levels with a cumulative probability of 0.69.
3 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, Cochrane, and Web of Science for randomized controlled trials (RCTs) published before November 2024 that investigated the use of anti-diabetic medications in patients with HF.
Summary · context
Primary outcomes included re-admission due to HF, all-cause death, cardiovascular death, serum N-terminal pro-brain natriuretic peptide (NTpro-BNP) levels, and left ventricular ejection fraction (LVEF).
Summary · context
A Bayesian network meta-analysis was used to compare the effectiveness of different anti-diabetic drugs.
Show in the study text Report a problemFND-4016059001
02HumanSystematic reviewEfficacy outcome
In reviewed HF patients, liraglutide had the best network efficacy for reducing NTpro-BNP, with reported cumulative probability 0.69; the probability definition was unstated.
In plain wordsIn reviewed HF patients, liraglutide ranked best for NTpro-BNP reduction with reported cumulative probability 0.69; its definition was unstated.
Peptide
Liraglutide
Outcome
Not applicableNTpro-BNP reduction efficacy ranking
Study
n: not reported in source
Comparator
Other network antidiabetic treatments
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
Cumulative probability
0.69
as reported for NTpro-BNP-reduction efficacy; definition unspecified; probability interpretation unspecified
Source sentences
Summary
Liraglutide reduced the risk of cardiovascular death in HF patients with a cumulative probability of 0.97 and had the best efficacy in reducing NTpro-BNP levels with a cumulative probability of 0.69.
3 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, Cochrane, and Web of Science for randomized controlled trials (RCTs) published before November 2024 that investigated the use of anti-diabetic medications in patients with HF.
Summary · context
Primary outcomes included re-admission due to HF, all-cause death, cardiovascular death, serum N-terminal pro-brain natriuretic peptide (NTpro-BNP) levels, and left ventricular ejection fraction (LVEF).
Summary · context
A Bayesian network meta-analysis was used to compare the effectiveness of different anti-diabetic drugs.
Show in the study text Report a problemFND-4016059002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.